From the Guidelines
Yes, the second dose of Trumenba can be given more than 4 weeks apart from the first dose. The recommended schedule for the two-dose series is to administer the second dose 6 months after the first dose, but the minimum interval between doses is not explicitly stated as a maximum in the provided evidence 1. However, it is mentioned that if the second dose of MenB-FHbp is administered at an interval of ≥6 months, a third dose does not need to be administered, implying flexibility in the dosing schedule 1.
Key Considerations
- The immune system has "memory," so even with a longer interval between doses, the second dose will effectively boost the immune response initiated by the first dose.
- Completing the full vaccination series is crucial to ensure adequate protection against meningococcal B disease, which can cause serious infections including meningitis and septicemia.
- If following the alternative three-dose schedule, the recommended timing is 0,1-2, and 6 months 1.
Administration Guidance
- For persons at increased risk for meningococcal disease and for use during serogroup B meningococcal disease outbreaks, 3 doses of MenB-FHbp should be administered at 0,1–2, and 6 months 1.
- For healthy adolescents who are not at increased risk for meningococcal disease, 2 doses of MenB-FHbp should be administered at 0 and 6 months 1.
From the Research
Meningococcal Serogroup B Vaccine Administration
- The recommended schedule for the meningococcal serogroup B vaccine, Trumenba, is a 2-dose schedule (0,6 months) for healthy individuals and a tailored 3-dose schedule (0,1-2,6 months) for those at increased risk 2.
- There is no direct evidence in the provided studies to suggest that the second dose of Trumenba can be given more than 4 weeks apart from the first dose.
- The studies focus on the development, safety, and efficacy of meningococcal serogroup B vaccines, including Trumenba, but do not provide specific guidance on the flexibility of the dosing schedule 3, 4, 5, 6.
- The clinical development program for MenB-FHbp (Trumenba) has demonstrated its safety and immunogenicity in adolescents and adults, supporting its licensure and immunization recommendations 5.